Advanced searches left 3/3

Temsirolimus - DOAJ

Summarized by Plex Scholar
Last Updated: 05 August 2022

* If you want to update the article please login/register

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma

Despite increased adherence to combination chemotherapy regimens, the majority of patients recover within a few years of therapy. Several proteins along the mTOR pathway can be upregulated in these and other forms of lymphoma in this and other forms of lymphoma, according to scientific studies on aberrant molecular pathways in cancer. rapamycin, CCI-779, MCL, mTOR, PI3K, Akt, Temsirolimus is the first mTOR inhibitor to have shown clinical success in treating MCL treated as a result of frontline therapies.

Source link: https://doaj.org/article/510fc3ae7e3547d7965f1b06635600f9


Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Objectives: To determine the clinical safety and cost-effectiveness of bevacizumab, interferon, sorafenib, syloglobinib, and temsirolimus in the treatment of patients with advanced and/or metastatic renal cell carcinoma. In terms of progression-free survival and tumor response, bevacizumab plus IFN or sunitinib had clinically relevant and statistically significant advantages over treatment with IFN alone, as well as doubling median progression-free survival and tumor responses from nearly 5 months to ten months. Temsirolimus had similar advantages over IFN in terms of progression-free and overall survival, declining-free survival, and tumour response, up from 0. 53 percent to 0. 60 percent, with a doubling in progression-free survival ratio from 0. 73 percent to 0. 60 percent, with improved median overall survival up from 0. 73 percent to 0. 8 percent, respectively, with a doubling of progression-free survival 0. 53 to 0. 60 percent CI 0. 73; 95% confidence interval 0. 73 to 0. 69 Although PenTAG and the intervention's developers have many similarities in their method and structural assumptions, in all cases, PenTAG's cost-effectiveness estimates were higher than those published in the manufacturer's U2019 submissions. Conclusions: Bevacizumab plus IFN and sunitinib therapy has clinically valid and statistically significant benefits over chemotherapy with IFN alone in patients with metastatic RCC. Both temsirolimus and IFN-treated patients had clinically relevant benefits over chemotherapy, IFN-based therapy, and sorafenib tosylate was superior to best supportive care as second-line therapy in people with three of six risk factors for poor prognosis.

Source link: https://doi.org/10.3310/hta14020


Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma

Temsirolimus is an inhibitor of rapamycin kinase, a protein that has been shown to be particularly active in metastatic renal cell carcinoma with poor prognosis. Therefore, temsirolimus should be considered as the first-line therapy indicated in mRCC patients who are at risk of being disadvantaged.

Source link: https://doi.org/10.1177/1756287215574457


Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Abstract Background The 7th cause of cancer death in men and the 10th in women is caused by bronchial cancer. Vinflunine was the only second-line chemotherapy available to patients who relapsed until recently. In more than half of bladder tumors, deregulation of the PI3K/AKT/mTOR pathway was observed, and mTOR therapy was suggested that the use of mTOR has been suggested as a target for treating urothelial cancers. Methods This study examined the efficacy of temsirolimus in a homogenous population of patients with recurrent or metastatic bladder cancer following first-line chemotherapy. Conclusions While the positivity of this trial points to a potential benefit of temsirolimus for a subset of bladder cancer patients who are resistant to first line platinum-based chemotherapy, a subset of bladder cancer patients who are resistant to first line platinum-based chemotherapy should be accounted for if such a possibility exists in this frail population.

Source link: https://doi.org/10.1186/s12885-018-4059-5


Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew (Cryptotis parva)

Temsirolimus triggered a dramatic and dose-dependent rise in both the mean urin frequency and the number of shrews vomiting with maximum efficiency at 10 mg/kg. Our observational findings showed that temsirolimus can reduce the shrew motor activity to 40 mg/kg, and later, we investigated the motor effects of its lower doses. A c-fos induction in the AP and NTS, but not DMNX with the 10 mg/kg emetic dose of temsirolimus demonstrated by immunochemistry for c-fos expression, although its larger antiemetic dose 20 mg/kg had no effect, although the c-fos induction was no significant.

Source link: https://doi.org/10.3389/fphar.2022.848673


Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma

Patients with mantle cell lymphoma have a poor prognosis, according to the University of Pisa, Italy, new therapeutic approaches, such as rapamycin and its derivates, a mammalian target of rapamycin inhibitors, are warranted. Temsirolimus, a dihydroester of rapamycin in MCL cell lines, downregulated p21 and v-Raf, which led to autophagy in MCL patients, according to the first clinical trial in MCL patients. Patients were randomly selected from two different doses or a regimen chosen by the investigator in an investigation that was one of the most commonly used single agents for treating relapsed MCL. Patients treated with 175/75 mg of temsirolimus had significantly improved response rates and longer progression-free survival than those treated with investigator’s choice therapy.

Source link: https://doaj.org/article/84586d1da37140908a7a04d6738ef19b


Resistance to the mTOR Inhibitor Temsirolimus Alters Adhesion and Migration Behavior of Renal Cell Carcinoma Cells through an Integrin α5– and Integrin β3–Dependent Mechanism

Inhibitors of the mammalian target of rapamycin have improved renal cell carcinoma therapy, according to Inhibitors of renal cell carcinoma. However, chronic drug use could lead to resistance, limiting the use of these drugs. Integrin's u03b1 and u03b2 subtype receptors were analyzed by flow cytometry and Western blot analysis. Integrin was reduced inside the cell and cell surface, but not at the plasma membrane, as shown by the u03b15 subtype. In RCCpar, blocking u03b15 surface receptors boosts RCC-collagen formation but reduced RCC-fibronectin interaction, while RCCes showed the opposite. The u03b15 antibody in RCCpar weakened Chemotaxis of RCCpar but not of RCCres was significantly reduced by the u03b15 antibody, but not of RCCres. Compared to RCCpar, significantly reduced chemotaxis with greater effects on RCCres, especially in comparison to RCCpar. Quantitative changes of integrin u03b15 and u03b23 expression, as well as functional changes of the integrin molecules, characterize Temsirolimus resistance, prompting a switch from RCC adhesion to RCC migration.

Source link: https://doi.org/10.1016/j.neo.2014.03.011


Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro

In prostate cancer, the mechanistic target of rapamycin is elevated, making this protein useful for tumor therapy. We investigated whether epigenetic modulation by the histone deacetylase inhibitor, valproic acid, could mask non-responsiveness to the mTOR inhibitor, temsirolimus, in prostate cancer cells. Compared to VPA and tumor cell growth rates, prostate cancer cells, sensitive and resistant to temsirolimus, were exposed to TEMsirolimus. In the G2/M-phase, Temsirolimus resistance raised the number of tumor cells in the G2/M-phase, contributing to increased cell proliferation and clonal expansion. Cdk1 and cyclin B decreased, as did phosphorylated mTOR and the mTOR subcomplex Raptor, as did phosphorylated mTOR and the mTOR sub-complex Raptor.

Source link: https://doi.org/10.3390/cancers11040566


A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.

Advanced renal cell carcinoma treatments, including temsirolimus and everolimus, have been approved for use in advance renal cell carcinoma therapy. However, the mTOR kinase is embedded in two distinct multiprotein complexes, mTORC1 and mTORC2, and both of these proteins may be key regulators of cell metabolism, expansion, and proliferation, which can be very useful regulators of cell growth and proliferation. In preclinical models of renal cell carcinoma, Ku0063794 was compared to temsirolimus. In vitro, Ku0063794 was more effective than temsirolimus in lowering the viability and growth of RCC cell lines Caki-1 and 786-O, but not apoptosis, although not apoptosis. A potential explanation is that temsirolimus has additional effects on the tumor microenvironment. HUVEC cells in vitro were grown in vitro at physiologically relevant concentrations in this case, but not Ku0063794, reduced tumor angiogenesis in vivo, and decreased HUVEC cell viability in vitro. In addition, Caki-1 and 786-O cells treated with temsirolimus were lower in Caki-1 and 786-O cells treated with temsirolimus than cells treated with Ku0063794.

Source link: https://doi.org/10.1371/journal.pone.0054918


Relapsed and/or Refractory Mantle cell Lymphoma: What Role for Temsirolimus?

Mantle Cell Lymphoma is associated with a dismal prognosis. Early combination results point to promising results at this time, and early combination studies have shown promising results. At this time, this drug has been shown to be safe as a single agent for relapsed disease. In addition, we've included a brief summary of other treatment options, we want to investigate which place in the latest treatment protocols Temsirolimus can be integrated into MCL patients's care.

Source link: https://doi.org/10.4137/CMO.S7327

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions